EBO2 (EBOO) research, annotated

This is every peer-reviewed paper we have found on EBO2 (also called EBOO), plus the ozone-therapy literature that clinics most often cite. For each one we record what kind of study it is, how many people were in it, what the authors reported, and what limits how much the result can tell you. We do not include conference abstracts, marketing white papers, or unpublished clinic data.

The short version: the EBOO-specific literature is small, dates mostly from the early-to-mid 2000s, and comes largely from the group that developed the technique. No large, independent, randomized trial has been published. Read the complete guide for how this fits together.

Studies of EBO2 / EBOO specifically

Case report · n = 1

Observed Reduction in Urinary Toxin Excretion With Extracorporeal Blood Oxygenation and Ozonation (EBOO) Treatment in an 88-Year-Old With Chronic Anemia: A Case Report

Bennett SJ, Kuo J, Wang S, et al.. Cureus, 2025. PMID 41583215.

Population: 88-year-old woman with chronic iron-deficiency anemia and environmental toxin burden

Reported finding: Across two series of EBOO treatments, urinary toxin/creatinine ratios declined on average by 64.8% for mycotoxins, 25.7% for heavy metals, and 55.1% for other environmental toxins, though nickel levels did not decline, while hemoglobin levels remained largely unchanged.

Limitations: Single-patient case report with no control for ongoing environmental exposure between measurements; findings cannot establish causation or generalize beyond this one patient.

In vitro

Oxygenation-ozonation of blood during extracorporeal circulation: in vitro efficiency of a new gas exchange device

Bocci V, Zanardi I, Travagli V, et al.. Artificial Organs, 2007. PMID 17725702.

Reported finding: Bench testing of a new hollow-fiber gas exchange device (L001) for EBOO, using a buffered saline solution containing KI rather than blood, showed efficient gas transfer with minimal foreign surface contact and negligible priming volume across the tested parameters.

Limitations: In vitro test on a saline solution, not blood or patients, with no clinical outcomes; PubMed lists no study-design publication type, so "in vitro" is inferred from the described bench methodology; authored by the EBOO technique's developers.

Narrative review

Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy

Di Paolo N, Gaggiotti E, Galli F. Redox Report, 2005. PMID 16156950.

Reported finding: Describes the EBOO technique (continuous extracorporeal filtration plus oxygen/ozone exchange) and argues it delivers a more controlled ozone dose to a larger blood volume than major autohemotherapy.

Limitations: Narrative review authored by the technique's developers; presents rationale and early observations rather than new controlled outcome data.

Randomized controlled trial · n = 28

Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease

Di Paolo N, Bocci V, Salvo DP, et al.. International Journal of Artificial Organs, 2005. PMID 16288443.

Population: Patients with peripheral artery disease

Reported finding: In 28 patients randomized to EBOO or intravenous prostacyclin, EBOO produced significantly greater regression of ischemic skin lesions and improved pain and well-being, with no significant difference in measured arterial circulation between groups.

Limitations: Small sample of 28 patients from a single Italian center; the available abstract does not describe blinding of outcome assessment or the randomization method.

Case report · n = 1

Necrotizing fasciitis successfully treated with extracorporeal blood oxygenation and ozonization (EBOO)

Di Paolo N, Bocci V, Cappelletti F, et al.. International Journal of Artificial Organs, 2002. PMID 12518965.

Population: Dialysis patient with necrotizing fasciitis unresponsive to standard therapy

Reported finding: A dialysis patient with necrotizing fasciitis who had not improved with traditional therapies improved radically after treatment with EBOO, which the authors describe as already used routinely at their hospital.

Limitations: Single case report from the technique's own developers; no control patient, randomization, or blinding, and no long-term follow-up reported.

Case report

Extracorporeal blood oxygenation and ozonation (EBOO) in man. preliminary report

Di Paolo N, Bocci V, Garosi G, et al.. International Journal of Artificial Organs, 2000. PMID 10741810.

Population: Early human recipients of EBOO, including patients with atherosclerotic vasculopathy

Reported finding: In the first human use of the EBOO apparatus, an author who self-tested the device noted disappearance of lipomas after six treatments; the device was then used in a patient with Madelung disease and several patients with atherosclerotic vasculopathy, with reported clinical benefit and no observed side effects.

Limitations: Uncontrolled preliminary case series performed by the device's own inventors, including self-experimentation; no blinding, randomization, or precisely reported total sample size.

Safety and adverse events

Other

Associations between particulate matter air pollutants and hospitalization risk for systemic lupus erythematosus: a time-series study from Xi'an, China

Pan Y, Fang Y, Chen Y, et al.. Environmental Geochemistry and Health, 2023. PMID 36287357.

Reported finding: A time-series study in Xi'an, China linked fine and coarse particulate matter with increased hospital admissions for systemic lupus erythematosus, while finding no significant association between ambient ozone (O3) and SLE admissions.

Limitations: An ecological, population-level air-pollution study of ambient exposure, not any ozone therapy; cannot show what a controlled medical ozone exposure does in an individual patient.

Randomized controlled trial · n = 118

Combining Ozonated Autohemotherapy with Pharmacological Therapy for Comorbid Insomnia and Myofascial Pain Syndrome: A Prospective Randomized Controlled Study

Shen W, Liu N, Ji Z, et al.. Pain Research & Management, 2022. PMID 37214227.

Population: Patients with comorbid insomnia and myofascial pain syndrome

Reported finding: In a randomized trial of 118 patients, adding ozonated autohemotherapy to standard pharmacological therapy improved sleep quality, pain, and mood more than pharmacological therapy alone, with no adverse complications observed in either group.

Limitations: Single-center trial without placebo control or blinding; safety was judged by observed complications rather than systematic adverse-event monitoring.

Case report · n = 1

Ozone therapy induced sinus arrest in a hypertensive patient with chronic kidney disease: A case report

Tang WJ, Jiang L, Wang Y, et al.. Medicine (Baltimore), 2017. PMID 29390373.

Population: 54-year-old woman with hypertension, diabetes, and chronic kidney disease

Reported finding: A patient using ozone autohemotherapy for hypertension and diabetes developed sudden dizziness from hyperkalemia that progressed to sinus arrest; the arrhythmia resolved after stopping ozone therapy and treating the hyperkalemia.

Limitations: Single case report; the association between ozone autohemotherapy and hyperkalemia-induced sinus arrest is based on temporal sequence, not confirmed mechanistic causation.

Narrative review

Health effects of ozone. A critical review

Lippmann M. JAPCA (Journal of the Air Pollution Control Association), 1989. PMID 2659744.

Reported finding: A critical review of inhaled ambient ozone air pollution finding that peak levels common in US air cause measurable transient lung-function changes, respiratory symptoms, and airway inflammation, with animal data suggesting cumulative structural lung damage from repeated exposure.

Limitations: Covers inhaled ambient ozone air pollution, not any medical ozone therapy; describes breathing exposure, not the injected or blood-contact routes clinics use.

Other

Ozone: a possible cause of hemolytic anemia in glucose-6-phosphate dehydrogenase deficient individuals

Calabrese EJ, Kojola WH, Carnow BW. Journal of Toxicology and Environmental Health, 1977. PMID 846014.

Reported finding: A theoretical model predicting that people with glucose-6-phosphate dehydrogenase (G6PD) deficiency may experience acute hemolysis on exposure to ozone at levels reached in polluted urban air.

Limitations: A theoretical, computational model of inhaled ambient ozone, not an experiment on blood or on any ozone therapy procedure; does not test the brief controlled blood contact EBO2 or MAH use.

Ozone therapy more broadly

Cohort study · n = 40

Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome

Kuculmez O. Frontiers in Medicine, 2026. PMID 41767530.

Population: Patients diagnosed with post-COVID syndrome

Reported finding: A retrospective review of 40 patients given 10 sessions of major ozone autohemotherapy for post-COVID syndrome found statistically significant improvement in anxiety, depression, fatigue, and quality-of-life scores after treatment.

Limitations: Retrospective single-center chart review with no control group and no blinding; a before-after comparison cannot rule out natural recovery or other concurrent care.

Other

SIOOT recommendations for the optimal application of the oxygen-ozone therapy in clinical medicine

Franzini M, Vaiano F, Tirelli U, et al.. International Immunopharmacology, 2025. PMID 39657536.

Reported finding: A professional-society position paper arguing that oxygen-ozone therapy needs standardized protocols and physician training, stating that inconsistent practice currently limits safety, efficacy, and reproducibility across the field.

Limitations: A recommendations and position statement from an ozone-therapy society (SIOOT), not a controlled study; reports no new patient outcomes or trial data of its own.

Randomized controlled trial · n = 73

A pilot randomized controlled trial of major ozone autohemotherapy for patients with post-acute sequelae of COVID-19

He Y, Liu X, Zha S, et al.. International Immunopharmacology, 2024. PMID 39018686.

Population: Patients with post-acute sequelae of COVID-19

Reported finding: In a pilot RCT, 35 patients given major ozone autohemotherapy plus conventional therapy had a higher symptom-score response rate (71%) than 38 given conventional therapy alone (45%), with better walk distance and lung function measures.

Limitations: The authors describe it as a pilot needing validation; tests major autohemotherapy, not EBO2, and the abstract does not describe blinding of outcome assessment.

Systematic review / meta-analysis · n = 424

Intra-articular injections of ozone versus hyaluronic acid for knee osteoarthritis: a level I meta-analysis

Migliorini F, Giorgino R, Mazzoleni MG, et al.. European Journal of Orthopaedic Surgery & Traumatology, 2024. PMID 39579218.

Population: Patients with knee osteoarthritis, pooled from randomized trials comparing ozone with hyaluronic acid

Reported finding: A level-I meta-analysis pooling 424 patients from randomized trials found intra-articular ozone injections produced pain scores (visual analogue scale) statistically similar to hyaluronic acid injections at 4-6 months follow-up.

Limitations: Restricted to studies with 4-6 month follow-up, so longer-term comparative efficacy is unknown; only ozone-versus-hyaluronic-acid comparisons were analyzed, with no placebo arm.

Narrative review · n = 271

Clinical effectiveness of medical ozone therapy in COVID-19: the evidence and gaps map

Serra MEG, Baeza-Noci J, Abdala CVM, et al.. Medical Gas Research, 2023. PMID 37077114.

Population: Patients across 13 pooled clinical studies of medical ozone therapy in COVID-19

Reported finding: An evidence-and-gaps map of 13 clinical studies (271 patients total) on medical ozone therapy for COVID-19, mostly major or minor autohemotherapy or rectal insufflation in acute, often hospitalized infection.

Limitations: Authored by ozone-therapy society members; maps existing acute-COVID studies rather than long COVID, and includes no EBO2-specific study.

Case report · n = 1

Sjögren syndrome successfully treated with oxygen-ozone auto-hemotherapy (O2-O3-AHT). A case report

Valdenassi L, Rossi E, Corsetti MT, et al.. European Review for Medical and Pharmacological Sciences, 2022. PMID 36066166.

Population: Older adult with Sjögren syndrome

Reported finding: A single older patient with Sjögren syndrome reported reduced pain and fatigue after a course of oxygen-ozone major autohemotherapy.

Limitations: One patient, no control group, and no blinding; cannot separate any ozone effect from the natural course of the disease or other concurrent care.

Systematic review / meta-analysis

A systematic review of ozone therapy for treating chronically refractory wounds and ulcers

Wen Q, Liu D, Wang X, et al.. International Wound Journal, 2022. PMID 34612569.

Population: People with chronic wounds and ulcers, mainly diabetic foot ulcers, pooled from 12 randomized trials

Reported finding: Pooling 12 randomized trials of topical or systemic ozone therapy for chronic wounds, this review found ozone accelerated wound-area improvement and reduced amputation rate for diabetic foot ulcers versus standard care, though complete wound healing rates and hospital stay did not differ, with no reported adverse events attributed to ozone across included studies.

Limitations: Included trials varied widely in ozone delivery method and wound type; the authors state evidence for wound types other than diabetic foot ulcers remains uncertain due to insufficient studies.

Cohort study · n = 100

Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy, preliminary results on 100 patients

Tirelli U, Franzini M, Valdenassi L, et al.. European Review for Medical and Pharmacological Sciences, 2021. PMID 34604980.

Population: Patients with post-COVID fatigue

Reported finding: In 100 patients with post-COVID fatigue, a preliminary, uncontrolled series of oxygen-ozone autohemotherapy reported reduced fatigue scores after treatment.

Limitations: No comparison group, so how much of the change would have occurred anyway cannot be determined; preliminary results from ozone-therapy society-affiliated authors.

Narrative review

Ozone and oxidation therapies as a solution to the emerging crisis in infectious disease management: a review of current knowledge and experience

Rowen RJ. Medical Gas Research, 2019. PMID 31898609.

Reported finding: A narrative review arguing ozone therapy could serve as an adjunctive or stand-alone treatment for drug-resistant infections and outbreaks such as Ebola, describing it as having a strong safety record.

Limitations: A single author's advocacy-oriented narrative review with no systematic search or new controlled data, and no study of ozone against Borrelia or Lyme disease specifically.

Randomized controlled trial · n = 80

Therapeutic Effect of Medical Ozone on Lumbar Disc Herniation

Niu T, Lv C, Yi G, et al.. Medical Science Monitor, 2018. PMID 29611536.

Population: Patients with trauma-induced lumbar disc herniation

Reported finding: In 80 patients randomized to control or low, medium (40 ug/mL), or high (60 ug/mL) concentrations of medical ozone, the medium concentration produced the greatest disc retraction and reduced inflammatory markers, while the highest concentration increased inflammatory marker expression instead of reducing it.

Limitations: Single-center trial; the abstract does not describe blinding; biochemical and imaging surrogate endpoints are emphasized alongside clinical pain scores.

Systematic review / meta-analysis · n = 212

Ozone therapy for treating foot ulcers in people with diabetes

Liu J, Zhang P, Tian J, et al.. Cochrane Database of Systematic Reviews, 2015. PMID 26505864.

Population: People with diabetic foot ulcers, pooled from 3 randomized controlled trials

Reported finding: This Cochrane review pooled 3 small randomized trials (212 participants): one found greater ulcer-area reduction and shorter hospitalization with ozone versus antibiotics, but pooled analysis of the other two found no significant difference from usual care in ulcer healing, adverse events, or amputation rate.

Limitations: Only three included trials, all judged at high or unclear risk of bias; the review authors conclude they are unable to draw any firm conclusions about effectiveness.

Controlled trial (non-randomized) · n = 15

Sports massage with ozonised oil or non-ozonised oil: comparative effects on recovery parameters after maximal effort in cyclists

Paoli A, Bianco A, Battaglia G, et al.. Physical Therapy in Sport, 2013. PMID 23623301.

Population: Competitive amateur male cyclists

Reported finding: In a within-subject comparison of 15 cyclists, sports massage with ozonised oil produced higher peak power and lower perceived fatigue after fatiguing exercise than massage without ozone or passive rest.

Limitations: Topical ozonised massage oil, not autohemotherapy or EBO2; a small single-center sample measuring short-term performance rather than any clinical outcome.

Randomized controlled trial · n = 140

Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study

Borrelli E, Diadori A, Zalaffi A, et al.. International Journal of Ophthalmology, 2012. PMID 23275905.

Population: Patients with dry age-related macular degeneration

Reported finding: In a randomized controlled trial of 140 patients, 27 sessions of major ozonated autohemotherapy over 12 months preserved visual acuity relative to multivitamin therapy and increased plasma antioxidant potential, with no loss of visual acuity in treated eyes versus substantial losses in controls.

Limitations: PubMed does not tag this as a randomized controlled trial, so the design is inferred from the abstract's own description; a co-author is a leading proponent of ozone therapy, and masking of outcome assessors is not described.

Systematic review / meta-analysis

Ozone therapy as a treatment for low back pain secondary to herniated disc: a systematic review and meta-analysis of randomized controlled trials

Magalhaes FN, Dotta L, Sasse A, et al.. Pain Physician, 2012. PMID 22430658.

Population: Patients with chronic low back pain secondary to herniated disc

Reported finding: A systematic review of 8 observational studies and meta-analysis of 4 randomized trials found percutaneous ozone injection (intradiscal or paravertebral) associated with positive pain outcomes and low morbidity, graded as evidence level II-1 to II-3 depending on route of injection.

Limitations: The authors themselves note a lack of precise diagnostic criteria and frequent use of mixed therapeutic agents across studies, that included trials were mainly active-control, and that no placebo-controlled trial was found.

Narrative review

Ozone therapy: a clinical review

Elvis AM, Ekta JS. Journal of Natural Science, Biology, and Medicine, 2011. PMID 22470237.

Reported finding: A general clinical review describing ozone's history, proposed mechanisms (antimicrobial action, immune stimulation), application methods, and the range of conditions it has been marketed for.

Limitations: A broad narrative review without a systematic search or a stated evidence grade for the conditions it lists; does not address EBO2 specifically.

Mechanistic and laboratory work

Narrative review

Dialysis membranes and hemodialyzers

Clark WR, Lorenzin A, Ronco C. Contributions to Nephrology, 2026. PMID 42721103.

Reported finding: A nephrology review of how hollow-fiber hemodialysis membranes are classified by pore size and permeability, and how pore size determines which molecules a filter can remove by convection.

Limitations: Describes dialysis and hemodiafiltration membranes generally, not any EBO2 device specifically, and includes no ozone-related content.

Narrative review

Advances in ozone technology for preservation of grains and end products: application techniques, control of microbial contaminants, mitigation of mycotoxins, impact on quality, and regulatory approvals

Sitoe EDPE, Pacheco FC, Chilala FD. Comprehensive Reviews in Food Science and Food Safety, 2025. PMID 40260769.

Reported finding: A food-science review of how gaseous ozone controls microbes and mycotoxins in stored grain, describing ozone's biocidal mechanism and regulatory approvals for food preservation.

Limitations: Entirely about industrial food and grain preservation, not human medicine or blood therapy; provides no evidence about mycotoxin removal from blood by EBO2 or any ozone therapy.

Narrative review

Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association

Gianos E, Duell PB, Toth PP, et al.. Arteriosclerosis, Thrombosis, and Vascular Biology, 2024. PMID 39370995.

Reported finding: An American Heart Association statement on lipoprotein apheresis, an FDA-regulated extracorporeal procedure shown to substantially lower LDL cholesterol and lipoprotein(a) through a specific filtration mechanism.

Limitations: Reviews an established, evidence-graded procedure for cholesterol removal; does not evaluate EBO2 or claim that EBO2's filter achieves comparable, measured lipid removal.

In vitro

Ozone dialysis delivers three or more times the ozone than other forms of ozone blood treatment

Rowen RJ, Grabovac S, Su TB. Medical Gas Research, 2023. PMID 36204785.

Reported finding: Measuring ozone uptake during continuous countercurrent blood flow across a dialysis membrane ("ozone dialysis"), the authors report at least three times higher ozone uptake than other blood-ozone delivery methods, describing it as the first quantitative comparison of its kind.

Limitations: Single-clinic measurement reported by the technique's own practitioner-developers rather than an independent or peer-replicated comparison; PubMed lists no study-design type, so "in vitro" is inferred; no patient outcomes are reported.

Case series · n = 6

Ozone high dose therapy (OHT) improves mitochondrial bioenergetics in peripheral blood mononuclear cells

König B, Lahodny J. Translational Medicine Communications, 2022. PMID 35880042.

Reported finding: In 6 patients given two 10-pass ozone high-dose therapy (OHT) sessions within a week, a laboratory bioenergetic health index in blood cells improved, driven mainly by increased mitochondrial reserve capacity.

Limitations: Six patients, no control group; a laboratory biomarker rather than a symptom or clinical outcome, co-authored by the technique's own developer. The abstract does not state a specific cumulative ozone dose in micrograms.

Narrative review

Oxidative stress, antioxidants, hormesis and calorie restriction: the current perspective in the biology of aging

Mehdi MM, Solanki P, Singh P. Archives of Gerontology and Geriatrics, 2021. PMID 33845417.

Reported finding: A narrative review of how oxidative stress, antioxidant defenses, and hormesis (a low-dose stress producing a protective response) are theorized to shape biological aging.

Limitations: A general biology-of-aging review with no mention of ozone or EBO2; describes hormesis as a broad concept, not evidence that any ozone procedure slows aging.

Cohort study · n = 20

The effects of oxygen-ozone therapy on regulatory T-cell responses in multiple sclerosis patients

Tahmasebi S, Qasim MT, Krivenkova MV, et al.. Cell Biology International, 2021. PMID 33724614.

Population: Relapsing-remitting multiple sclerosis patients

Reported finding: In 20 relapsing-remitting MS patients treated with ozone autohemotherapy twice weekly for 6 months, regulatory T-cell frequency and related anti-inflammatory markers (FoxP3, IL-10, TGF-beta) rose after treatment compared with before.

Limitations: Single-arm before-after design with no untreated control group and no blinding; measures a laboratory immune marker, not a clinical disability or symptom outcome.

Cohort study · n = 20

Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patients

Izadi M, Tahmasebi S, Pustokhina I, et al.. Multiple Sclerosis and Related Disorders, 2020. PMID 32862036.

Population: Multiple sclerosis patients

Reported finding: In 20 MS patients, the authors' own "non-controlled study" found ozone autohemotherapy lowered the frequency of pro-inflammatory Th17 cells and related markers after treatment compared with before.

Limitations: The authors describe it as non-controlled; a before-after comparison in one treated group measuring a laboratory immune marker rather than disability or symptom outcomes.

Narrative review

Ozone: a natural bioactive molecule with antioxidant property as potential new strategy in aging and in neurodegenerative disorders

Scassellati C, Galoforo AC, Bonvicini C, et al.. Ageing Research Reviews, 2020. PMID 32810649.

Reported finding: A mechanistic review proposing that controlled, low-dose ozone activates the Nrf2 antioxidant pathway, and arguing this could be relevant to aging and neurodegenerative disease.

Limitations: A hypothesis-generating narrative review, not a clinical trial; cites laboratory and animal mechanism data rather than a human outcome linking ozone exposure to slower aging.

Animal study · n = 10

Effects of ozonated autohemotherapy on the antioxidant capacity of Thoroughbred horses

Tsuzuki N, Endo Y, Kikkawa L, et al.. Journal of Veterinary Medical Science, 2016. PMID 26166812.

Population: Thoroughbred racehorses

Reported finding: In 10 Thoroughbred horses, ozonated autohemotherapy raised a blood marker of antioxidant capacity (biological antioxidant potential) compared with a control group at 3 and 7 days after treatment.

Limitations: Animal study, not human; measures a general antioxidant blood marker rather than any disease outcome, and does not test EBO2's continuous-filtration circuit.

Narrative review

The ozone paradox: ozone is a strong oxidant as well as a medical drug

Bocci V, Borrelli E, Travagli V, et al.. Medicinal Research Reviews, 2009. PMID 19260079.

Reported finding: Explains that prolonged ozone inhalation is toxic to the lungs and body, whereas a single, precisely calibrated ozone dose dissolved in blood ex vivo triggers antioxidant and biochemical responses in blood cells and endothelium that the authors describe as therapeutically useful without toxicity in selected diseases.

Limitations: Narrative review by long-time ozone-therapy proponents that synthesizes prior mechanistic work rather than presenting new controlled data.

Narrative review

Ozone as Janus: this controversial gas can be either toxic or medically useful

Bocci V. Mediators of Inflammation, 2004. PMID 15203558.

Reported finding: Argues that ozone, though intrinsically toxic as an inhaled gas, produces a cascade of ozone-derived compounds when dissolved in blood at judicious, physician-controlled doses, yielding multifactorial beneficial effects in infections, vasculopathies, and orthopedic and dental conditions.

Limitations: Single-author narrative review without a systematic search methodology or quantitative synthesis of the underlying evidence.

Controlled trial (non-randomized) · n = 12

No effects of ozonated autohemotherapy on inflammation response in hemodialyzed patients

Tylicki L, Biedunkiewicz B, Rachon D, et al.. Mediators of Inflammation, 2004. PMID 15770057.

Population: Chronically hemodialyzed patients with peripheral arterial disease

Reported finding: In a controlled, single-blind, cross-over study of 12 hemodialysis patients, nine sessions of ozonated autohemotherapy produced no significant change in plasma C-reactive protein or interleukin-6 compared with nine sham (oxygen-only) autohemotherapy sessions.

Limitations: Small sample of 12 patients in a single crossover study; a null result for these two inflammatory markers does not rule out other biological effects of ozone.